Galderma says new Nemluvio data show sustained atopic dermatitis improvements up to three years

Galderma Group said Arcadia open-label long-term extension data showed Nemluvio (nemolizumab) was well-tolerated and associated with sustained improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents aged at least 12 with moderate-to-severe atopic dermatitis up to 200 weeks, including at week 152.